NEOS Investment Management’s Cytokinetics CYTK Stock Holding History

NEOS Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,278	Closed	-$844K	–	601
2025 Q4	$844K	Sell	13,278 -8,306	-38%	-$517K	﹤0.01%	566
2025 Q3	$1.19M	Sell	21,584 -2,412	-10%	-$99.4K	0.01%	495
2025 Q2	$793K	Sell	23,996 -8,592	-26%	-$299K	0.01%	493
2025 Q1	$1.31M	Sell	32,588 -14,795	-31%	-$680K	0.02%	400
2024 Q4	$2.23M	Sell	47,383 -3,075	-6%	-$160K	0.05%	281
2024 Q3	$2.66M	Buy	50,458 +391	+0.8%	+$21.8K	0.08%	221
2024 Q2	$2.71M	Buy	50,067 +24,477	+96%	+$1.48M	0.11%	169
2024 Q1	$1.79M	Buy	25,590 +18,924	+284%	+$1.46M	0.11%	177
2023 Q4	$557K	Buy	+6,666	New	+$241K	0.05%	267

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

NEOS Investment Management's CYTK Position: Q1 2026 in Review

NEOS Investment Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 13,278 shares — an estimated $844K sold.

NEOS Investment Management first reported a position in CYTK in Q4 2023 and held it in 9 quarters. The position peaked at $2.71M in Q2 2024. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

NEOS Investment Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
NEOS Investment Management sold 13,278 Cytokinetics shares in Q1 2026, an estimated $844K.
NEOS Investment Management first reported a position in Cytokinetics in Q4 2023 and held it in 9 quarters.
NEOS Investment Management's Cytokinetics position peaked at $2.71M in Q2 2024.
440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.